The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.
|Slideshows|December 14, 2017
New Neurosurgery Tech of Interest to Neurologists
Author(s)Veronica Hackethal, MD
A summary of cutting-edge technology, including the world’s smallest fully implantable spinal cord neurostimulator for the treatment of chronic pain.
Advertisement
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.
A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.
A phase 1b/2 trial is testing an intrathecal antisense oligonucleotide designed to lower KCNT1 expression in children with a severe, drug-resistant epilepsy syndrome.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Remibrutinib Lowers Relapse Rate vs Teriflunomide in Relapsing MS
2
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
3
Tenecteplase Benefit Before Thrombectomy Varies by Stroke Cause, Study Shows
4
Phase 2 ACUITY Analysis Shows Privosegtor Associated With Smaller Early NfL and GFAP Increases in Acute Optic Neuritis
5